About Us

Elliot Lebowitz, Ph.D.

Dr. Lebowitz holds a B.A. from Columbia College and a Ph.D. from

Columbia University.  He serves on the Board of Directors of Stem Cell

Sciences,  Ltd., which is a leader in stem cell technology. From

2003-2004 he served  as  President of the Theseus Imaging Corporation, a developer of products for in-vivo imaging. Dr.Lebowitz served as the

founding Chief Executive Officer of  BioTransplant, Inc. from 1991-2002,

a company that worked closely with the TBRC in studies to enhance  human acceptance of transplanted organs.  From 1985-1991, he served as Vice President  for Research and Development at C. R. Bard, Inc., a medical device company, directing internal and collaborative research and development programs for  Bard's Vascular Systems, Cardiosurgery and Cardiopulmonary Divisions. From 1981-1985, Dr. Lebowitz served as Director of Long Range Research and Development at DuPont Corporation, a diversified health care company, developing  immunopharmaceuticals. From 1977-1981, he served as Division Manager of the  Medical Products Division of New England Nuclear Corporation, a developer,  manufacturerand marketer of radiopharmaceuticals for in-vivo diagnosis, which  was acquired by DuPont Corporation in 1981. Earlier in his career, Dr. Lebowitz  served at Brookhaven National Laboratories, where he developed Thallium-201, a  radiopharmaceutical for the diagnosis of coronary artery disease. Dr. Lebowitz was a founder of Diagnostic Isotopes, Inc. a radiopharmaceutical company which  was subsequently acquired by Hoffman-La Roche Inc.  He was also a founder of Procept, Inc., a biopharmaceutical company which focused on rational drug design. Dr. Lebowitz is currently in the process of founding a new company to address the shortage of human donor organs and cells by developing anexpanded supply from donor porcine cells and organs.